Avalo Therapeutics (AVTX) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" AVTX shares.
View AVTX analyst ratings or view top-rated stocks.

1 analysts have issued 12 month target prices for Avalo Therapeutics' stock. Their AVTX share price forecasts range from $10.00 to $21.00. On average, they anticipate the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 411.6% from the stock's current price.
View analysts price targets for AVTX or view top-rated stocks among Wall Street analysts.

Avalo Therapeutics' stock was trading at $5.0401 at the beginning of the year. Since then, AVTX stock has decreased by 39.9% and is now trading at $3.03.
View the best growth stocks for 2023 here.

Avalo Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 43,800 shares, an increase of 17.1% from the April 30th total of 37,400 shares. Based on an average daily trading volume, of 48,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.4% of the shares of the company are sold short.
View Avalo Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AVTX earnings forecast.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its quarterly earnings data on Wednesday, March, 2nd. The company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.80) by $0.12. Avalo Therapeutics had a negative trailing twelve-month return on equity of 950.78% and a negative net margin of 170.36%.

Avalo Therapeutics's stock reverse split on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

Avalo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (33.44%), Great Point Partners LLC (3.60%), Alyeska Investment Group L.P. (3.03%), Braidwell LP (1.87%) and Monashee Investment Management LLC (0.45%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends.

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVTX stock can currently be purchased for approximately $3.03.

Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $40.00 million and generates $18.05 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis.

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com.